Shares of Large-cap health care company DexCom moved -0.9 this afternoon, and are now trading at $94.47 per share. On the other hand, the average analyst target price for the stock is $146.28.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Potential DexCom Investors Should Analyze the Following:
-
DexCom has moved 8.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 2.12. A number between 0 and 1 could mean that the market is undervaluing DexCom's estimated growth potential
-
Its Price to Book (P/B) ratio is 17.37
Understanding DexCom's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-09 | 2,909,800 | -1,491,900 | 13 | -7.14 |
| 2022-02-14 | 2,448,500 | -1,327,600 | 14 | -12.5 |
| 2021-02-11 | 1,926,700 | -980,600 | 16 | 60.0 |
| 2020-02-13 | 1,476,000 | -789,200 | 10 | 233.33 |
| 2019-02-21 | 1,031,600 | -632,500 | 3 | 150.0 |
| 2018-02-27 | 718,500 | -534,600 | -6 |
Over the last 6 years, DexCom's operating margins have averaged only 8.3%, with a high coefficient of variability of 100.3%. On the other hand, we note that the firm's margins are growing at a 21.6% compounded average yearly rate.
